Selpercatinib (Retevmo): A Breakthrough Cancer Therapy What is Selpercatinib (Retevmo)? Selpercatinib, supplied as 40 mg and 80 mg capsules for oral use under the brand name Retevmo, is a targeted
Ustekinumab (Stelara): Medication Guide Introduction Ustekinumab, marketed under the brand name Stelara, is a monoclonal antibody. Monoclonal antibodies are specific proteins that identify and bind
Cushing’s Disease: Understanding and Managing the Condition Introduction Cushing’s disease is a rare but serious condition caused by an overproduction of cortisol, a hormone produced by the
FDA Approves New Treatment for HER2-Positive Colorectal Cancer Introduction The FDA has approved a new treatment for some patients with advanced colorectal cancer. This treatment is specifically for
Retevmo (Selpercatinib) Indications Retevmo (selpercatinib) is an oral kinase inhibitor designed for the treatment of specific types of cancers. Its primary indications include: Non-Small Cell Lung
Blincyto (Blinatumomab) Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager approved for treating adult and pediatric patients aged 1 month and older with CD19-positive B-cell
FDA Approval of Bkemv (Eculizumab-aeeb) May 28th, 2024: In a significant milestone for the treatment of rare diseases, the U.S. Food and Drug Administration (FDA) approved Bkemv (eculizumab-aeeb) as
Tibsovo (Ivosidenib) Indications: Tibsovo is a prescription medication used to treat adult patients with an IDH1 mutation in the following conditions: Acute Myeloid Leukemia (AML): For newly
